Vivesto AB
VIVE
Rank in Stocks
#30973
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes... Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
Share Price
$0.74479082
Last synced: 2026-11-09
Market Cap
$4.01M
Change (1 day)
5.09%
Change (1 year)
-70.21%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vivesto AB (VIVE)
Category
Healthcare
Operating Margin for Vivesto AB (VIVE)
Operating Margin as of November 2026 TTM: 0.00%
According to Vivesto AB's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Vivesto AB from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2022 | -35,144.73% | 7,055.31% |
| 2021 | -491.17% | 3,194.23% |
| 2020 | -14.91% | -99.75% |
| 2019 | -6,067.27% | 85.37% |
| 2018 | -3,273.08% | -95.99% |
| 2017 | -81,675.00% | 3,822.76% |
| 2016 | -2,082.08% | -60.18% |
| 2015 | -5,228.26% | -96.80% |
| 2014 | -163,485.00% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | -7,355.33% | -87.88% |
| 2011 | -60,710.38% | 124,638.81% |
| 2010 | -48.67% | 439.58% |
| 2009 | -9.02% | 32.26% |
| 2008 | -6.82% | -83.76% |
| 2007 | -42.00% | -94.82% |
| 2006 | -810.05% | -100.00% |
| 2005 | -30,261,936.36% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | - |
DE
|
|
| 19.68% | - |
DE
|
|
| 13.26% | - |
JP
|
|
| 17.08% | - |
CH
|
|
| 14.92% | - |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Vivesto AB's operating margin
What was Vivesto AB's operating margin in 2025?
In 2025, Vivesto AB's operating margin was 0.00%, compared with 0.00% in 2024.
How has Vivesto AB's operating margin changed since 2020?
From 2020 to 2025, Vivesto AB's operating margin was highest in 2025 (0.00%) and lowest in 2022 (-35,144.73%).
How does Vivesto AB's operating margin compare with similar companies?
Vivesto AB's operating margin (0.00%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.